Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab
The venture group that has launched a fleet of new biotechs in recent years, piecing together billions in syndicate cash, has $824 million more to build its next generation of life sciences companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
